Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra Class Action Lawsuit Requests Medical Monitoring, Product Ban

This article was originally published in The Tan Sheet

Executive Summary

A nationwide class action lawsuit against 16 ephedra firms requests the creation of a "medical monitoring program and/or rehabilitation program" to provide medical testing and monitoring to all people who have taken ephedra-containing dietary supplements

You may also be interested in...



GNC Liability In Ephedra Lawsuits Is Limited, Numico Says

Rexall Sundown and GNC have been named in 137 product liability lawsuits involving ephedrine alkaloid-containing dietary supplements, former parent company Royal Numico disclosed in a year-end financials release March 4

GNC Liability In Ephedra Lawsuits Is Limited, Numico Says

Rexall Sundown and GNC have been named in 137 product liability lawsuits involving ephedrine alkaloid-containing dietary supplements, former parent company Royal Numico disclosed in a year-end financials release March 4

GNC Liability In Ephedra Lawsuits Is Limited, Numico Says

Rexall Sundown and GNC have been named in 137 product liability lawsuits involving ephedrine alkaloid-containing dietary supplements, former parent company Royal Numico disclosed in a year-end financials release March 4

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel